Development of a novel exosome-based enzyme replacement therapy for the treatment of human lysosomal storage disease (LSDs) - PROJECT SUMMARY
Development of a novel exosome-based enzyme replacement therapy for the
treatment of human lysosomal storage diseases
Intracellular delivery of protein therapeutics has transformative impact on the treatment of devastating
human diseases like cancer, infection and hereditary disorders. Lysosomal storage diseases (LSDs) are
the largest group of hereditary metabolic disorders caused by a deficiency of lysosomal enzymes.
Current standard of treatment for LSDs is enzyme replacement therapy (ERT) using recombinant
enzymes. However, ERT is only available to 6 out of 50 LSDs and the recombinant enzymes are
extremely expensive ($200,000/year for the life) and only produce limited benefits in mild to moderate
patients. Moreover, ERT has no effects in severe cases with vital organ involvements such as brain, heart
and lung, presumably attributable to the poor bioavailability of these tissues to recombinant enzymes.
Exosomes are cell-derived nano-vesicles that play an important role in mediating cell-to-cell
communication. As nano-carriers, exosomes can shuttle a large amount of macromolecules between
various tissues and organs. Because their intrinsic tissue-penetrating ability, exosomes represent a new
and promising class of nanomedicine for intracellular targets. However, the lack of engineering strategy
to load protein therapeutics onto exosomes has become a major hurdle for exosome-based nano-
medicine. We aim to develop a novel genetic approach for producing enzyme-loaded exosomes for
the potential treatment of LSDs. For proof in concept, we choose Gaucher disease, one of the most
common types of LSDs, as our study model. In this proposed study we will: (1) establish genetic
strategies for loading β-glucocerebrosidase (GBA) enzymes via anchoring vesicular stomatitis virus
glycoprotein (VSVG) onto exosomes in human producing cells, and determine molecular pathways of
exosome-targeting and therapeutic enzyme loading onto exosomes using fluorescence monitoring and
confocal microscope techniques, (2) establish procedures of exosome purification, and characterize the
physical and biochemical properties of the isolated exosomes as well as their ability for targeted delivery
of loaded lysosomal enzymes to recipient human cells, (3) establish GBA knockout human cell model and
employ it to determine the safety and efficacy of enzyme replacement with enzyme-loaded exosomes.
Successful completion of this study will build a novel and general platform of ERT for the potential
treatment of Gaucher disease and other LSDs with neurological complications.
